| Assessment Status |
Rapid Review Complete |
| HTA ID |
26042 |
| Drug |
Cemiplimab |
| Brand |
Libtayo® |
| Indication |
Cemiplimab (Libtayo®) is indicated as monotherapy for the adjuvant treatment of adult patients with cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation. |
| Rapid review commissioned |
24/08/2026 |
| Rapid review completed |
14/09/2026 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost-effectiveness of cemiplimab (Libtayo®) compared with the current standard of care. |
